Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$32.12 USD
+0.08 (0.25%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $32.03 -0.09 (-0.28%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TARS 32.12 +0.08(0.25%)
Will TARS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy
Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?
Other News for TARS
Commit To Buy Tarsus Pharmaceuticals At $15, Earn 7.6% Annualized Using Options
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Tarsus refinances existing debt with $200M financing commitment
Tarsus Pharmaceuticals Secures $75M Loan for Growth and Debt Repayment